Merck & Co. Inc. (MRK): One of the Best Low Risk High Growth Stocks to Buy Right Now

robot
Abstract generation in progress

Merck & Co., Inc. (MRK) is highlighted as a top low-risk, high-growth stock, successfully navigating patent expirations by diversifying its oncology, cardiovascular, and vaccine portfolios. The company’s future growth is de-risked by new drugs like Winrevair, which is projected to be a $5 billion+ annual revenue generator, and continued strong performance from its HPV vaccine Gardasil and new RSV prevention medication ENFLONSIA. With a low Beta of 0.26 and a forward P/E of approximately 20x, MRK is attractive to investors, though the article also suggests exploring AI stocks for higher upside potential.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments